Greenwich LifeSciences reports significant immune response in Phase III breast cancer trial
Greenwich LifeSciences (NASDAQ:GLSI) today presented a significant update on its clinical progress at the 2026 American Association for Cancer Research (AACR) Annual Meeting.










